Dec 18 (Reuters) - MetaVia Inc :
* METAVIA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE 2A CLINICAL TRIAL OF DA-1241 IN PATIENTS WITH PRESUMED MASH
* DA-1241 VERY WELL TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS
* DA-1241 SHOWS SIGNIFICANT REDUCTION IN ALT LEVELS AT WEEKS 4 AND 8
* DA-1241 100MG SHOWS SIGNIFICANT IMPROVEMENTS IN CAP SCORE AT WEEK 16
* DA-1241 100MG SHOWS SIGNIFICANT REDUCTIONS IN HBA1C AT WEEK 16
* EXPECTS END OF PHASE 2 MEETING WITH FDA IN FIRST HALF OF 2025
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。